UNSPSC 51111855: Lanreotide

This classification denotes a somatostatin receptor agonist with the molecular formula C54H69N11O10S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0G3DE8943Y, chemically known as l-threoninamide, 3-(2-naphthalenyl)-d-alanyl-l-cysteinyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl-l-cysteinyl-, cyclic (2-7)-disulfide but generally known as lanreotide, which bears US NIH Compound Identifier 71349. European Medicines Agency schedules Lanreotide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08402MIG.

UNSPSC 51111855 Lanreotide is a Commodity code covering the procurement of lanreotide, a somatostatin analog pharmaceutical used to treat acromegaly and neuroendocrine tumors in state and local health systems, correctional facilities, and public hospital networks. State and local governments purchase lanreotide through pharmacy benefit managers, group purchasing organizations, and direct vendor agreements to stock it in inpatient and outpatient treatment settings. The issuing bodies for this code span state departments of health, state prison systems, county health departments, municipal hospitals, and independent hospital districts that operate their own formularies and drug procurement channels.

The source provided contains no recent state or local contract opportunities under UNSPSC 51111855. Without posted RFPs, RFQs, IBFs, or ITBs naming this code, no geographic concentration or representative recent solicitations can be characterized from current market activity.